http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2015264956-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d9a31243981e8241cc00b1f1094bc23 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-10 |
| filingDate | 2015-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3908616b3d35bddd20393e9cbfd1eaaa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5e61eaf0454a9c0b625863ff461f34c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98fce2ef0e88979b7021c7a167d2740a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcbc0020718c4dbcef2923a014266183 |
| publicationDate | 2015-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2015264956-A1 |
| titleOfInvention | Anchorage devices comprising an active pharmaceutical ingredient |
| abstract | TYRX 3.4-010 An anchorage device 100 comprising a mesh substrate 124 coupled to an implantable medical device 120 is disclosed, where the mesh substrate has a coating 120 comprising a polymer, and the mesh further comprises at least one active pharmaceutical ingredient. The active pharmaceutical agent is designed to elute from the device over time. The mesh substrate can be configured to reduce the mass of the anchorage device such that tissue in-growth and/or scar tissue formation at the treatment site is reduced. In some embodiments, the mesh substrate can be formed with a mesh having a low areal density. In some embodiments, the mesh substrate can include one or more apertures or pores to reduce the mass of the substrate. -60- |
| priorityDate | 2010-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 444.